Form 4: Teva Pharmaceutical Industries Executive Receives Restricted Share Units

David R. McAvoy, EVP and Chief Legal Officer of Teva Pharmaceutical Industries, was granted 66,964 restricted share units on March 4, 2024, according to a Form 4 filing.

Summary

• David R. McAvoy, the EVP and Chief Legal Officer of Teva Pharmaceutical Industries, received 66,964 restricted share units on March 4, 2024.
• These restricted share units represent a contingent right to receive one ordinary share or the cash value of one ordinary share at settlement.
• The restricted share units vest in four equal installments of 16,741 units on March 4 of 2025, 2026, 2027, and 2028.
• The filing was signed on March 5, 2024, by Dov Bergwerk as attorney-in-fact for David R. McAvoy.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard executive compensation practice. It's neither particularly positive nor negative from an investment perspective.

Positives

• The grant of restricted share units aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Executive compensation packages often include restricted share units to incentivize performance and align executive interests with shareholder value. This is a common practice in the pharmaceutical industry.

Stakeholder Impact

• Shareholders may view the grant as a positive sign of aligning management interests with long-term company performance.
• Employees may see this as a standard part of executive compensation.

Key Dates